Online-Trading Portfolio-Tracker Research Back-Office MF-Tracker
BSE Prices delayed by 5 minutes... << Prices as on Apr 29, 2024 >>   ABB 6451.7 [ 0.67 ]ACC 2526.15 [ 0.07 ]AMBUJA CEM 629.8 [ -0.36 ]ASIAN PAINTS 2868.1 [ 0.83 ]AXIS BANK 1159.45 [ 2.60 ]BAJAJ AUTO 8759.8 [ -2.29 ]BANKOFBARODA 272.7 [ 1.70 ]BHARTI AIRTE 1333.25 [ 0.58 ]BHEL 276.8 [ -0.72 ]BPCL 618.7 [ 1.53 ]BRITANIAINDS 4800.95 [ 0.07 ]CIPLA 1407.55 [ -0.13 ]COAL INDIA 453.2 [ -0.52 ]COLGATEPALMO 2826.5 [ -1.01 ]DABUR INDIA 506.65 [ -0.46 ]DLF 886.25 [ -2.36 ]DRREDDYSLAB 6293.5 [ 0.64 ]GAIL 209.55 [ 0.72 ]GRASIM INDS 2388.05 [ 1.82 ]HCLTECHNOLOG 1387.1 [ -5.79 ]HDFC 2729.95 [ -0.62 ]HDFC BANK 1528.8 [ 1.26 ]HEROMOTOCORP 4458.4 [ -0.74 ]HIND.UNILEV 2226.95 [ 0.25 ]HINDALCO 650.2 [ 0.10 ]ICICI BANK 1158.8 [ 4.67 ]IDFC 121.65 [ -4.40 ]INDIANHOTELS 583.1 [ 2.60 ]INDUSINDBANK 1487.75 [ 2.90 ]INFOSYS 1435 [ 0.34 ]ITC LTD 438 [ -0.44 ]JINDALSTLPOW 941.9 [ 1.07 ]KOTAK BANK 1640.25 [ 1.98 ]L&T 3633.9 [ 0.88 ]LUPIN 1637.55 [ 1.34 ]MAH&MAH 2062.85 [ 0.91 ]MARUTI SUZUK 12695.75 [ 0.07 ]MTNL 37.61 [ 0.13 ]NESTLE 2510.6 [ 1.08 ]NIIT 107.8 [ -0.09 ]NMDC 254.9 [ -1.12 ]NTPC 363.1 [ 2.07 ]ONGC 283.3 [ 0.16 ]PNB 137.25 [ 0.59 ]POWER GRID 293.7 [ 0.55 ]RIL 2930.5 [ 0.95 ]SBI 826.15 [ 3.09 ]SESA GOA 406.3 [ 2.43 ]SHIPPINGCORP 232.45 [ 0.02 ]SUNPHRMINDS 1521.95 [ 1.18 ]TATA CHEM 1099 [ -2.09 ]TATA GLOBAL 1098.9 [ -0.36 ]TATA MOTORS 1000.45 [ 0.11 ]TATA STEEL 167.4 [ 0.93 ]TATAPOWERCOM 448.1 [ 2.60 ]TCS 3870.6 [ 1.51 ]TECH MAHINDR 1288.8 [ 0.89 ]ULTRATECHCEM 9962.25 [ 2.70 ]UNITED SPIRI 1180.6 [ -1.59 ]WIPRO 462.95 [ -0.37 ]ZEETELEFILMS 149.35 [ 2.33 ] BSE NSE
You can view the entire text of Notes to accounts of the company for the latest year

BSE: 530233ISIN: INE292C01011INDUSTRY: Pharmaceuticals

BSE   ` 214.00   Open: 227.90   Today's Range 202.00
227.90
+1.70 (+ 0.79 %) Prev Close: 212.30 52 Week Range 64.00
227.90
Year End :2018-03 

A. The following explain the material adjustments made while transition from previous Accounting Standards to Ind AS.

a. Fair value of security deposits:

Under the previous GAAP, interest free security deposits are recorded at transactions value. Under Ind AS, all financial assets are required to be fair valued.

b. Other comprehensive income:

Under Ind AS all items of income and expenses recognised in the period should be included in the profit & loss for the period, unless a Standard requires or permits otherwise.

Items of income and expenses that are not recognised in the statement of profit & loss but are shown in the statement of profit or loss as other comprehensive income includes re-measurement of defined benefit plans. The concept of other comprehensive income did not exist under previous GAAP.

c. Deferred tax :

Deferred tax impact on the above adjustments.

d. Retained earnings:

Retained earnings as at 1st April, 2016 has been adjusted consequent to the above Ind AS transition adjustments.

B. Summary of the Company’s exposure to credit risk by age of the outstanding from various customers is as follows:

The Ageing analysis of Account receivables has been considered from the date the invoice falls due:

C. Capital Management

The company’s objectives when managing capital are to

i) Safeguard their ability to continue as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders, and maintain an optimal capital structure to reduce the cost of capital. The Company monitors capital using a ratio of ‘adjusted net debt’ to ‘adjusted equity’. For this purpose, adjusted net debt is defined as total liabilities, comprising interest-bearing loans and borrowings and obligations under finance leases, less cash and cash equivalents. Adjusted equity comprises all components of equity.

D. Balance of Trade Receivables and Trade payable are subject to confirmations

I. SEGMENT INFORMATION_

Based on the guiding principles given in the Accounting Standard 17 on “Segment Reporting” issued by The Institute of Chartered Accountants of India, the Company is a single segment Company engaged in the business of Bulk Drugs.

II. Previous year’s figures have been regrouped, rearranged and reclassified wherever necessary.